Falsely Elevated Liver Stiffness: Inflammation, Cholestasis, Congestion
Clinical Issue
Liver elastography is often perceived as a direct measurement of fibrosis, but this is incorrect. The method measures the mechanical stiffness of the tissue, which depends on fibrosis, sinusoidal pressure, inflammatory edema, biliary pressure, blood filling, and technical conditions. In the update WFUMB Liver Multiparametric Ultrasound: Part 1, 2024, these factors are considered key confounders that can increase liver stiffness measurement (LSM) without a corresponding increase in fibrosis stage.
Practical takeaway: increased LSM should not automatically translate to F3–F4 if there is concurrent acute hepatitis, significant cytolytic activity, mechanical jaundice, right heart failure, or signs of hepatic venous congestion.
WFUMB Guidelines: When Values Require Caution
WFUMB provides a universal 'rule of four' approach for assessing the risk of compensated advanced chronic liver disease (cACLD). These guidelines do not replace etiological and device-specific thresholds but help understand how dangerous an LSM value is and when confounders are particularly critical.
| LSM, kPa | Interpretation by WFUMB 2024 | Practical Action with Possible Confounder |
|---|---|---|
| ≤5 | High likelihood of normal liver stiffness | Search for fibrosis only with strong clinical-laboratory grounds |
| <9 | In the absence of clinical signs, usually excludes cACLD | If inflammation or congestion is present, indicate that the result still does not support cACLD |
| 9–13 | Uncertainty zone; value may correspond to cACLD or be falsely elevated | Must correlate with ALT/AST, bilirubin, ALP/GGT, Doppler, clinical findings |
| >13 | Supports the diagnosis of cACLD | In cases of cholestasis, acute inflammation, or congestion, do not finalize fibrosis staging; repeat after correction |
| >17 | Indicates risk of clinically significant portal hypertension | Exclude venous congestion and cardiac cause of elevation; assess spleen, portal flow, ascites |
Inflammation: Cytolysis as a Cause of Elevated LSM
Active inflammation increases liver stiffness due to cellular edema, infiltration, necroinflammatory activity, and changes in intrahepatic microcirculation. Therefore, in acute viral, drug-induced, autoimmune, or ischemic injury, high LSM may reflect process activity rather than architectural liver remodeling.
A typical pitfall is a patient with high ALT/AST and first-time elastography. If LSM falls within the range suggesting cACLD but there are no signs of portal hypertension, thrombocytopenia, irregular contour, splenomegaly, or chronic history, the conclusion should be cautious: 'stiffness elevated, fibrosis stage interpretation limited by active inflammation.'
Cholestasis: Biliary Pressure Mimics Fibrosis
Extrahepatic biliary obstruction and significant cholestasis also increase liver stiffness. The mechanism is related to increased pressure in the biliary tree, edema of portal tracts, and reactive parenchymal changes. After decompression of the bile ducts, LSM may decrease, so fibrosis staging before obstruction resolution is unreliable.
In cases of intrahepatic duct dilation, common bile duct dilation, stones, tumor obstruction, or laboratory cholestatic profile, the elastography result should be interpreted as 'stiffness in the context of cholestasis.' This is especially important in the 9–13 kPa zone and at values >13 kPa, where the risk of overdiagnosing advanced fibrosis is highest.
Venous Congestion: Liver as a Right Heart Manometer
Increased central venous pressure is quickly transmitted to hepatic veins and sinusoids. In right ventricular failure, tricuspid regurgitation, constrictive pericarditis, volume overload, or acute heart failure decompensation, LSM can be high without cirrhosis.
Ultrasound signs that should halt automatic fibrosis staging: dilation of the inferior vena cava and hepatic veins, reduced collapse of the inferior vena cava, pulsatility of portal flow, cardiac ascites, hepatomegaly with tenderness. In such situations, LSM reflects hemodynamics, not just matrix fibrosis.
How to Distinguish True Fibrosis from False Elevation
Reliable interpretation is based not on a single number but on correlation. The protocol should indicate the clinical context, biochemistry, and grayscale/Doppler signs. Fibrosis is more indicated by an irregular liver contour, coarse echotexture, signs of portal hypertension, splenomegaly, and consistently elevated LSM outside of acute states. For a confounder — acute cytolysis, biliary obstruction, cardiac decompensation, or significant venous congestion.
If a confounder is present, it is more accurate not to write 'cirrhosis by elastography' based solely on LSM. It is better to formulate: 'liver stiffness elevated; fibrosis stage assessment limited by likely influence of inflammation/cholestasis/venous congestion.'
Technical Conditions: Do Not Mix Measurement Error and Biological Confounder
Falsely elevated LSM can be biological and technical. Biological is associated with a real increase in tissue stiffness without fibrosis; technical — with incorrect window, breathing, probe compression, inclusion of vessels, capsule, lesions, or artifacts. WFUMB emphasizes the need for standardized study performance and quality control of measurements.
For practice, it is important to separate these causes. If measurements are unstable, the area of interest falls on a vessel, or the patient cannot hold their breath, the result is better considered unreliable. If measurements are of good quality but cholestasis or congestion is present, the result reliably reflects increased stiffness but does not equal fibrosis stage.
What to Write in the Conclusion
The optimal conclusion consists of three parts: numerical LSM value, risk category according to applicable guidelines, and interpretation limitation. Example: 'LSM 12 kPa, uncertainty range by rule of four; considering laboratory cholestasis, fibrosis staging is limited, follow-up recommended after obstruction resolution.' For cardiac congestion: 'LSM elevated; signs of hepatic venous congestion detected, so the value may be hemodynamically driven.'
This style reduces the risk of incorrect cirrhosis diagnosis, unnecessary referral for invasive procedures, and erroneous prognosis assessment. At the same time, it does not devalue the result: high LSM in congestion or cholestasis remains clinically significant but answers a different question.
Algorithm for the Ultrasound Physician
- Assess for acute inflammation: clinical findings, ALT/AST, signs of active hepatitis.
- Exclude cholestasis: bilirubin, ALP/GGT, bile duct diameter, cause of obstruction.
- Check for venous congestion: inferior vena cava, hepatic veins, portal pulsatility, signs of right heart overload.
- Correlate LSM with WFUMB thresholds: <9, 9–13, >13, and >17 kPa.
- If a confounder is present, do not fix the final fibrosis stage; recommend repeat after stabilization.
Key Conclusion
Inflammation, cholestasis, and venous congestion are the three most important clinical causes of falsely elevated liver stiffness. In the 9–13 kPa range, they often determine further management, and at >13 kPa, they can lead to overdiagnosis of cACLD. According to WFUMB 2024, LSM should be interpreted as part of multiparametric ultrasound, not as an isolated surrogate for histology.
Frequently asked questions
Can cirrhosis be diagnosed solely based on high liver stiffness?
No, if there is active inflammation, cholestasis, or venous congestion. In these conditions, LSM can be falsely elevated relative to the fibrosis stage; clinical-laboratory correlation and repeat after confounder correction are needed.
Which LSM range is most problematic for interpretation?
According to the WFUMB 'rule of four' guideline, the 9–13 kPa range is the zone of uncertainty. This is where inflammation, cholestasis, and congestion most frequently alter result interpretation.
What should be done if LSM >13 kPa in the context of mechanical jaundice?
Indicate that the value supports the risk of cACLD, but fibrosis staging is limited by cholestasis. Ideally, repeat elastography after resolution of biliary obstruction and normalization of the clinical situation.